CompletedPhase 1NCT02373215

Phase 1 Study of Nalbuphine HCl ER Tablets in Hemodialysis Patients With Uremic Pruritus

Studying Uremic pruritus

Last synced from ClinicalTrials.gov April 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Trevi Therapeutics
Principal Investigator: Chief Development Officer
Trevi Therapeutics
Intervention: Nalbuphine HCL ER(drug)
Enrollment: 22 target
Eligibility: 18-70 years · All sexes
Timeline: 2013 – 2013

Collaborators

Davita Clinical Research

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT02373215 on ClinicalTrials.gov

Other trials for Uremic pruritus

Additional recruiting or active studies for the same condition.

RECRUITINGPHASE3NCT06446310
Phase 3 Study of QLG2198 in Haemodialysis Chinese Adult Subjects With Moderate-to-Severe Pruritus
Qilu Pharmaceutical (Hainan) Co., Ltd.

See all trials for Uremic pruritus →

← Back to all trials